Evidence map›Paper›PMID 42010954›Full record

ArticleJournal of primary care & community health

Impact of Medicaid Continuous Glucose Monitor Expansion on Uptake, Glycemic Outcomes, and Engagement Among Adults With Type 2 Diabetes in a Federally Qualified Health Center.

Walter Solorzano, Ligaya Docena Scarlett, Giuliana Perini Villanueva, Kathyana Santiago Mangual, Cynthia Santana, Bryan Escobar, Angelique Rubio, Nicholas J Jackson, Marielle Tavares, Joseph Borrell and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of primary care & community health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Walter SolorzanoUniversity of California, Los Angeles, USA.ORCID 0000-0002-7824-4342
Ligaya Docena ScarlettUniversity of California, Los Angeles, USA.ORCID 0009-0004-7400-2612
Giuliana Perini VillanuevaUniversity of California, Los Angeles, USA.ORCID 0009-0007-6761-0320
Kathyana Santiago MangualUniversity of California, Los Angeles, USA.ORCID 0009-0004-5079-941X
Cynthia SantanaUniversity of California, Los Angeles, USA.ORCID 0009-0007-9901-2990
Bryan EscobarUniversity of California, Los Angeles, USA.ORCID 0009-0005-9516-5768
Angelique RubioUniversity of California, Los Angeles, USA.
Nicholas J JacksonUniversity of California, Los Angeles, USA.ORCID 0000-0002-9515-5050
Marielle TavaresUniversity of California, Los Angeles, USA.ORCID 0009-0004-4391-7078
Joseph BorrellUniversity of California, Los Angeles, USA.
Beatrice BrumleyUniversity of California, Los Angeles, USA.
Tannaz MoinUniversity of California, Los Angeles, USA.ORCID 0000-0002-5035-6641
Estelle EverettUniversity of California, Los Angeles, USA.ORCID 0000-0002-7468-296X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundContinuous glucose monitors (CGMs) improve outcomes for adults with type 2 diabetes yet use remains low in underserved populations. California's 2022 Medicaid coverage expansion aimed to reduce access barriers, but its impact in safety-net settings is not well understood.

methodsWe conducted a retrospective cohort study of adults with type 2 diabetes receiving care at a federally qualified health center from January 2022 to June 2023. Electronic health records assessed CGM uptake and glycemic outcomes. Telephone surveys (November 2023-February 2025) evaluated patient perceptions and engagement. Time-to-event models estimated the association between CGM initiation and achieving a ≥1% hemoglobin A1c (HbA1c) reduction. Open-ended responses were analyzed thematically.

resultsAmong 256 adults, 126 (49%) initiated CGM use, with uptake increasing after Medicaid expansion. In the analytic sample (n = 230), CGM new users were associated with a higher but not statistically significant hazard of achieving a ≥1% HbA1c reduction (adjusted HR = 1.31; 95% CI: 0.87-1.97). Among survey respondents (n = 82), commonly cited benefits included improved glucose management and convenience, while engagement varied across behaviors.

conclusionsMedicaid coverage expansion increased CGM use in a safety-net population. High acceptability alongside variable engagement highlights the need for targeted implementation strategies to translate expanded access into equitable clinical benefit.

Indexed as

Continuous Glucose MonitoringDiabetes Mellitus, Type 2MedicaidAdultAgedBlood GlucoseBlood Glucose Self-MonitoringCaliforniaFemaleGlycated HemoglobinHealth Services AccessibilityHumansMaleMiddle AgedRetrospective StudiesSafety-net ProvidersBlood GlucoseGlycated Hemoglobincontinuous glucose monitoringfederally qualified health centershealth equityMedicaid policysafety-net healthcaretype 2 diabetes

Identifiers

PMID42010954
PMCPMC13111895

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.